代谢功能障碍相关疾病和酒精性肝病药物研发的新进展。

Zhang Jinming, Li Yixin, Yang Liu, Ma Ningning, Qian Shengying, Chen Yingfen, Duan Yajun, Xiang Xiaogang, He Yong

Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (USTC), Hefei, 230001, Anhui, China.

Cell Biosci. 2024 Jul 6;14(1):90. doi: 10.1186/s13578-024-01267-9.

Metabolic disorders are currently threatening public health worldwide. Discovering new targets and developing promising drugs will reduce the global metabolic-related disease burden. Metabolic disorders primarily consist of lipid and glucose metabolic disorders. Specifically, metabolic dysfunction-associated steatosis liver disease (MASLD) and alcohol-associated liver disease (ALD) are two representative lipid metabolism disorders, while diabetes mellitus is a typical glucose metabolism disorder. In this review, we aimed to summarize the new drug candidates with promising efficacy identified in clinical trials for these diseases. These drug candidates may provide alternatives for patients with metabolic disorders and advance the progress of drug discovery for the large disease burden.

代谢紊乱目前正在威胁全球公众健康。发现新靶点并开发有前景的药物将减轻全球与代谢相关的疾病负担。代谢紊乱主要包括脂质和葡萄糖代谢紊乱。具体而言，代谢功能障碍相关脂肪性肝病（MASLD）和酒精性肝病（ALD）是两种代表性的脂质代谢紊乱，而糖尿病是典型的葡萄糖代谢紊乱。在本综述中，我们旨在总结在这些疾病的临床试验中确定的具有有前景疗效的新药候选物。这些候选药物可能为代谢紊乱患者提供替代方案，并推动针对巨大疾病负担的药物研发进展。